BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 31, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2008

View Archived Issues

Recent patent literature reports novel anticancer compounds

Read More

Yi-Gan San studied in dementia, tardive dyskinesia and borderline personality disorder

Read More

VaxGen and Raven terminate merger agreement

Read More

Cardiac-specific MAP kinase protects against cardiac ischemia in vitro and in vivo

Read More

Evotec and Ono sign agreement to identify compounds against a protease target

Read More

Encouraging results reported in first clinical trial of efficacy for GFT-505

Read More

Positive phase III data reported for new GnRH blocker degarelix

Read More

Avanir to raise gross proceeds of USD 40 million in a registered direct offering

Read More

MethylGene enters agreement with Otsuka for small-molecule kinase inhibitors

Read More

MPA requests additional information prior to initiation of Tripeps' ChronSeal phase II study

Read More

Thallion defers start date of phase II/III clinical trial of Shigamabs by six months

Read More

Evotec reports preliminary findings from study of EVT-101 in healthy volunteers

Read More

Seattle Genetics initiates second phase I clinical trial of SGN-35 in Hodgkin's lymphoma

Read More

New therapeutic agents for diabetic nephropathy described in recent Kowa patent

Read More

Recent Amgen and Kyowa Hakko patents disclose novel analgesic agents

Read More

IMPACT1 study demonstrates efficacy of Berinert P in hereditary angioedema

Read More

DJ-1 provides neuroprotection against oxidative stress

Read More

Effects on survival seen with EGF vaccine in non-small cell lung cancer patients

Read More

Lilly commences phase III LY-450139 trial for Alzheimer's disease

Read More

NeuroSearch initiates phase I NSD-788 study for anxiety and depression

Read More

Synosia Therapeutics commences phase II rufinamide trial for general anxiety disorder

Read More

Protectan CBLB-502 shows mitigation of hematopoietic damage post-radiation

Read More

UCB reports phase II results for CDP-791 in non-small cell lung cancer

Read More

Phase I/II trial in CF patients begins for Humaneered antibody against P. aeruginosa infections

Read More

NeoPharm enrolls first patients in phase II cancer trial of liposomal paclitaxel

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing